GlycanAge, a London, UK-based biotech startup in the field of glycan biomarkers glycan biomarkers, raised $4.2M in Seed funding.
The round was led by LAUNCHub Ventures and Kadmos Capital.
The company intends to use the funds to expand operations and development efforts.
Led by CEO Nikolina Lauc, GlycanAge is a biotech company specializing in glycobiology and the science of biological aging. With its biological age test, the company provides personalized preventative healthcare, enabling individuals to make informed decisions about their health and lifestyle.
Commenting on the news, Nikolina Lauc said: “We are thrilled to have the support of LAUNCHub Ventures and Kadmos Capital, who share our vision for a healthier future. This funding round marks a significant milestone for GlycanAge, and we are excited to continue our journey towards transforming healthcare and empowering individuals to take control of their well-being.”
FinSMEs